Stratos Wealth Partners, Ltd. Protalix Bio Therapeutics, Inc. Transaction History
Stratos Wealth Partners, Ltd.
- $6.32 Billion
- Q1 2025
A detailed history of Stratos Wealth Partners, Ltd. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Stratos Wealth Partners, Ltd. holds 346,400 shares of PLX stock, worth $502,280. This represents 0.01% of its overall portfolio holdings.
Number of Shares
346,400
Previous 270,000
28.3%
Holding current value
$502,280
Previous $518,000
71.04%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.27MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.72 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.4 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.25 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$992,8990.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$891,8730.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $72.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...